Bullish For Biotech: Two Sizable Bets On Emerging Leaders Print E-mail
By M.E.Garza   
Tuesday, 25 September 2012 22:59
icon_TrendAnalysisWe can’t help but notice that more bankers and growth fund managers are placing bigger bets in biotech, where earnings results are not correlated with the macro environment.
Read more...
 
What Happens To Questcor Now? Print E-mail
By Brian Wilson, Contributor   
Tuesday, 25 September 2012 02:39
icon_SeekingDirectionQuestcor Pharmaceuticals, Inc.(NASDAQ:QCOR) shares plunged and lost more than a third of their value Monday after the company announced that it has become aware of a U.S. government investigation involving the Company's promotional practices.
Read more...
 
Weight Loss Stocks In Action Print E-mail
By Brian Wilson, Contributor   
Monday, 24 September 2012 06:08
icon_closerlookAnyone who has been following the world of emerging pharmaceutical companies in the last few months has probably heard a good amount about the two new FDA-approved prescription weight loss drugs Qsymia and Belviq.
Read more...
 
Following A Winner: Tracking The Investment Profile Of Isaac Blech Print E-mail
By Scott Matusow, Contributor   
Thursday, 20 September 2012 03:08
icon_stockresearchIn June, I wrote an article featuring a company called Medgenics (MDGN). Preparing for my article on the firm, I attended a conference call with management there and spoke with Isaac Blech-- a well known biotech investor in the 80's and 90's who took years off to focus on his family and things in life that mattered most to him.
Read more...
 
Interview: How 4.5MM Late-Stage Neuro Patients Drive Opportunity For MRI Interventions Print E-mail
By Staff and Wire Reports   
Tuesday, 18 September 2012 13:32
icon_ceoexclusive2.2 Million late-stage neuro-patients are "stranded", according to MRI Interventions (OTCBB:MRIC) CEO Kimble Jenkins, who explains that neurosurgeons have been performing minimally invasive brain surgeries using technologies dating back at least 60 years.
Read more...
 
Pluristem’s $32 Million Raise Puts Them in a New League Print E-mail
By Sharon di Stefano, Equity Brief   
Tuesday, 18 September 2012 03:08
icon_closerlookIn an otherwise choppy market, Pluristem Therapeutics (NASDAQ:PSTI) issued new shares with a new and noteworthy underwriter, declining other big name banks, raising enough money to give them at least five years of cash at their current burn rate.
Read more...
 
Seven Innovative Biotechs That Could Soar by Year-End: George Zavoico Print E-mail
By George S. Mack of The Life Sciences Report   
Friday, 14 September 2012 04:03
Biotech has a breeze to its back, and successful progression through the phases of drug development also help propel the industry forward.
Read more...
 
Q&A: Jacob BenArie, CEO of Orgenesis Print E-mail
By Staff and Wire Reports   
Wednesday, 12 September 2012 01:09
icon_qaexclusiveOrgenesis Inc. (OTCBB:ORGS) is developing a new technology for regeneration of functional insulin-producing cells, thus enabling normal glucose regulated insulin secretion, via cell therapy.
Read more...
 
Biotech Dividend Has Investors Taking Positions Print E-mail
By M.E.Garza   
Tuesday, 11 September 2012 07:08
icon_MarketCatalystTiming may have been a bit off, but things are finally heatig up as investors take positions ahead of stock dividend date.
Read more...
 
Repros Sees Renewed Confidence Print E-mail
By Brian Wilson, Contributor   
Friday, 07 September 2012 07:09
icon_marketmoverRepros Therapeutics (NASDAQ: RPRX) stock has rallied an impressive 60% in the last month on renewed confidence in the company's pipeline, which consists of the male fertility drug Androxal which inhibits estrogen receptors, and the female endometriosis and uterine fibroid treatment Proellex, which inhibits progesterone.
Read more...
 
<< Start < Prev 51 52 53 54 55 56 Next > End >>

Page 51 of 56

Newsletter